This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
by Zacks Equity Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 12.68% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study
by Zacks Equity Research
Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.
New Strong Sell Stocks for March 11th
by Zacks Equity Research
AVVIY, EBS, and NVEI have been added to the Zacks Rank #5 (Strong Sell) List on March 11, 2022.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
by Zacks Equity Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
by Zacks Equity Research
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Emergent (EBS) Begins Dosing in Study on Influenza Vaccine
by Zacks Equity Research
Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.
Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down
by Zacks Equity Research
Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.
Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -117.73% and -27.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Emergent Biosolutions (EBS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
by Zacks Equity Research
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
New Strong Sell Stocks for August 2nd
by Zacks Equity Research
ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU
by Zacks Equity Research
A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.
J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many
by Zacks Equity Research
J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Emergent (EBS) Issues Plan to Resume Bayview Facility Operation
by Zacks Equity Research
Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO